Stock ORY ORYZON GENOMICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Oryzon Genomics S.A.

Equities

ORY

ES0167733015

Biotechnology & Medical Research

Market Closed - BME
Other stock markets
 11:35:26 2024-04-26 am EDT 		5-day change 1st Jan Change
2 EUR +0.91% Intraday chart for Oryzon Genomics S.A. +5.60% +5.93%
Apr. 22 Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat CI
Apr. 08 ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 83.25 126.5 210.1 142.5 133.1 115.2 115.2 -
Enterprise Value (EV) 1 67.16 104.6 184.1 142.5 134.4 108.8 134.3 129.7
P/E ratio -71.9 x -30.2 x -53.1 x -30.9 x -33.1 x -34.1 x -18.1 x -12.1 x
Yield - - - - - - - -
Capitalization / Revenue 12.3 x - - - - - - -
EV / Revenue 9.9 x - - - - - - -
EV / EBITDA -24.2 x -28.4 x -44.4 x -20.7 x -25.3 x -23.4 x -34.6 x 29.4 x
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 38,455 45,489 60,035 52,762 53,663 57,614 57,614 -
Reference price 2 2.165 2.780 3.500 2.700 2.480 2.000 2.000 2.000
Announcement Date 2/15/19 2/24/20 2/23/21 2/7/22 2/17/23 2/26/24 - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 6.781 - - - - - - -
EBITDA 1 -2.77 -3.679 -4.145 -6.866 -5.323 -5.246 -3.882 4.412
EBIT 1 -10.18 -3.969 -4.339 -17.61 -21.45 -19.25 -21.47 -20.36
Operating Margin -150.2% - - - - - - -
Earnings before Tax (EBT) 1 -3.712 -4.576 -4.339 -6.939 -5.492 -4.634 -6.356 -1.352
Net income 1 -1.177 -3.809 -3.435 -4.639 -4.233 -3.415 -5.427 -0.4842
Net margin -17.36% - - - - - - -
EPS 2 -0.0301 -0.0921 -0.0659 -0.0874 -0.0750 -0.0553 -0.1103 -0.1650
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 2/15/19 2/24/20 2/23/21 2/7/22 2/17/23 2/26/24 - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2021 Q1 2021 Q2 2021 S1 2021 Q3 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 S2
Net sales 1 - - - - - - - - - - - - - - - - - - - - - - -
EBITDA - - - - - - - - - - - - - - - - - - - - - - -
EBIT 1 -1.623 -7.688 - - -3.318 - -5.145 -14.18 - -1.759 -3.363 -4.998 -5.891 - -4.841 -2.471 -4.244 -4.551 -4.923 -5.202 - -5.508 -
Operating Margin - - - - - - - - - - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -1.945 -2.155 -1.682 -1.575 -3.318 -1.541 -2.116 -3.497 -1.661 -1.753 -3.437 -0.694 -1.49 -1.614 -1.179 -3.272 -0.7798 -2.433 -1.701 -1.797 -3.2 -1.901 -3.2
Net income 1 -1.972 -1.307 -1.755 0.8 -1.019 -1.572 -2.062 -3.585 -1.725 0.3394 -1.298 -0.6261 -2.299 -1.614 1.041 -0.5682 -1.063 -1.638 -1.787 -1.883 -3.2 -2.007 -1.2
Net margin - - - - - - - - - - - - - - - - - - - - - - -
EPS 2 -0.0461 -0.0259 -0.0329 0.0168 -0.0168 -0.0257 -0.0350 -0.0700 -0.0286 0.009820 -0.0294 -0.0101 -0.0469 -0.0273 0.0181 -0.009030 -0.0189 -0.0270 -0.0280 -0.0280 -0.1000 -0.0325 -
Dividend per Share - - - - - - - - - - - - - - - - - - - - - - -
Announcement Date 2/24/20 7/22/20 5/7/21 7/29/21 7/29/21 10/28/21 2/7/22 2/7/22 5/5/22 7/22/22 7/22/22 11/2/22 2/17/23 5/10/23 7/24/23 7/24/23 10/27/23 - - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - 1.36 7.32 19.1 14.5
Net Cash position 1 16.1 21.9 26.1 - - - - -
Leverage (Debt/EBITDA) - - - - -0.256 x -1.395 x -4.92 x 3.28 x
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 0.17 0.12 0.15 0.18 0.08 0.08 0.05 0.05
Capex / Sales 2.5% - - - - - - -
Announcement Date 2/15/19 2/24/20 2/23/21 2/7/22 2/17/23 2/26/24 - -
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2 EUR
Average target price
6.676 EUR
Spread / Average Target
+233.82%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ORYZON GENOMICS S.A. Stock Oryzon Genomics S.A.
+5.93% 123M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ORY Stock
  4. Financials Oryzon Genomics S.A.